Genomics expansion Admera Health has recently expanded its sequencing capabilities with the launch of whole-genome sequencing on the Illumina NovaSeq X Plus, indicating an opportunity to cross-sell advanced WGS services to current researchers and biopharma partners seeking comprehensive genomic profiling.

Strategic collaborations Ongoing and recent partnerships with institutions and industry players (ODU collaboration on AI-based Alzheimer’s insights, Twist Bioscience as an NGS ProLab, Complete Genomics for spatial transcriptomics) present openings to propose integrated service packages and co-development projects with allied networks.

AI and analytics Investment in generative AI platforms for Alzheimer's research signals a differentiator for offering AI-assisted data analysis, predictive modeling, and advanced bioinformatics as value-added services to biopharma and research customers.

Grants and incentives Grants tied to research collaborations and a grant-driven Stereo-seq program create entry points for joint proposals with universities and research groups, enabling funded testing of Admera’s services and capabilities.

Global accessibility Partnerships to expand access and discounts for sequencing services suggest opportunities to upsell tiered service plans, volume-based pricing, and loyalty programs to large labs and multi-site researchers expanding their genomic projects.